

Form PTO-892 U.S. Department of Commerce	Serial Number 10/022,276	Group Art Unit 1623	Attachment to Paper Number	04
Notice of References Cited	APPLICANT(S) Gosselin et al.			

U. S. Patent Documents

*		DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	Filing Date If Appropriate
*	A	5 9 3 9 4 0 2	08/17/99	Weis et al. (I)	514	044.000	03/11/98
*	B	5 5 5 9 1 0 1	09/24/96	Weis et al. (II)	514	045.000	10/24/94
*	C	6 0 2 5 3 3 5	02/15/00	Weis et al. (III)	514	044.000	09/21/95

Foreign Patent Documents

*		DOCUMENT NO.	DATE	COUNTRY	NAME	CLASS	SUB-CLASS		
*	L	9 4 2 0 5 2 3	09/15/94	World(WO/PCT)	Burroughs Wellcome	-----	-----		
*	M	EP 0 352 248 A1	01/24/90	Europe(EPO)	Medivir Ak.	-----	-----		

Other References (Including Author, Title, Date, Pertinent Pages, etc.)

*	R	Robins, "Selective Deoxygenation and Modification at C2' of Nucleosides," pages 1-4 in <u>Nucleic Acids Research Symposium Series, Vol. No. 11</u>, Kyoto, Japan, November 24-26, 1982, A. E. Pritchard (ed.), IRL Press, Ltd., Oxford, England, 1982; see also <u>Chemical Abstracts</u>, <u>98</u>, Abstract No. 107670u (1982).
*	S	Verri et al., "Relaxed Enantioselectivity of Human Mitochondrial Thymidine Kinase and Chemotherapeutic Uses of L-Nucleoside Analogues," <u>Biochemical Journal</u>, <u>328</u>(1), 317-320 (November 15, 1997).
*	T	Lin et al., "Design and Synthesis of 2', 3'-Dideoxy-2', 3'-dideoxy-β-L-cytidine (β-L-d4C) and 2', 3'-Dideoxy-2', 3'-dideoxy-β-L-5-fluorocytidine (β-L-Fd4C), Two Exceptionally Potent Inhibitors of Human Hepatitis B Virus (HBV) and Potent Inhibitors of Human Immunodeficiency Virus (HIV) <i>In Vitro</i>," <u>Journal of Medicinal Chemistry</u>, <u>39</u>(9), 1757-1759 (April 26, 1996).

† Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.

EXAMINER L. Eric Crane	DATE 04/09/02	page 1 of 2 ¥: Reference not presently available.	DUPLICATE
*A copy of this reference is not being furnished with this office action. (See Manual of Patent Examining Procedure, Section 707.05(a).)			

Form PTO-892 U.S. Department of Commerce	Serial Number 10/022,276	Group Art Unit 1623	Attachment to Paper Number	04
Notice of References Cited	APPLICANT(S)			
	Gosselin et al.			

Other References (Including Author, Title, Date, Pertinent Pages, etc.)

*	U	von Janta-Lipinski et al., "Newly Synthesized L-Enantiomers of 3'-Fluoro-Modified β -2'-Deoxyribonucleoside 5'-Triphosphates Inhibit Hepatitis B DNA Polymerase But Not the Five Cellular DNA Polymerases α , β , γ , δ , and ϵ Nor HIV-1 Reverse Transcriptase," <u>Journal of Medicinal Chemistry</u> , <u>41</u> (12), 2040-2046 (June 4, 1996).
*	V†	Mansour et al., "Stereochemical Aspects of the Anti-HCMV Activity of Cytidine Nucleoside Analogues," <u>Antiviral Chemistry & Chemotherapy</u> , <u>6</u> (3), 138-142 (1995).
*	X†	Spadari et al., "L-Thymidine Is Phosphorylated by Herpes Simplex Type 1 Thymidine Kinase and Inhibits Viral Growth," <u>Journal of Medicinal Chemistry</u> , <u>35</u> (22), 4214-4220 (1992).
*	Y	Bryant et al., "Antiviral L-Nucleosides Specific for Hepatitis B Virus Infection," <u>Antimicrobial Agents and Chemotherapy</u> , <u>45</u> (1), 229-235 (January, 2001).
*	Z†	Wang et al., "Recovery of Liver Sinusoidal Endothelial Cell Function over Time After Hypothermic Preservation in Rat Orthotopic Liver Transplantation," AASLD Abstracts published in <u>Hepatology</u> , <u>24</u> (No. 4, Pt. 2), page 431A, Abstract No. 1219 (1996).††

† Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.

†† Copy supplied but not cited by applicant.

DUPLICATE

EXAMINER L. Eric Crane <i>[Signature]</i>	DATE 04/09/02	page 2 of 2 ¥: Reference not presently available.
*A copy of this reference is not being furnished with this office action. (See Manual of Patent Examining Procedure, Section 707.05(a).)		